BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
+$607M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$226M |
| 3 |
SPDR S&P Retail ETF
XRT
|
+$220M |
| 4 |
Health Care Select Sector SPDR Fund
XLV
|
+$179M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$131M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.2B |
| 2 |
Tesla
TSLA
|
+$652M |
| 3 |
Microsoft
MSFT
|
+$601M |
| 4 |
Apple
AAPL
|
+$520M |
| 5 |
iShares MSCI ACWI ETF
ACWI
|
+$362M |
Sector Composition
| 1 | Technology | 17.04% |
| 2 | Financials | 11.4% |
| 3 | Healthcare | 8.84% |
| 4 | Consumer Discretionary | 8.27% |
| 5 | Industrials | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Fortis
FTS
$24.8B
| $111K | ﹤0.01% |
2,500
| – | – |
|
2502
Entravision Communication
EVC
$213M
| $111K | ﹤0.01% |
15,608
-2,902
| -16% | -$20.6K |
|
2503
Vuzix
VUZI
$174M
| $110K | ﹤0.01% |
10,561
-2,891
| -21% | -$30.2K |
|
2504
Clarus
CLAR
$149M
| $110K | ﹤0.01% |
4,305
+3,156
| +275% | +$80.9K |
|
2505
Rigel Pharmaceuticals
RIGL
$669M
| $110K | ﹤0.01% |
3,024
+2,375
| +366% | +$86.2K |
|
2506
Smith & Nephew
SNN
$16.6B
| $110K | ﹤0.01% |
+3,196
| New | +$110K |
|
2507
PAVmed
PAVM
$9.32M
| $110K | ﹤0.01% |
856
+671
| +363% | +$85.9K |
|
2508
CNB Financial Corp
CCNE
$763M
| $110K | ﹤0.01% |
4,499
+2,116
| +89% | +$51.5K |
|
2509
Farmers National Banc Corp
FMNB
$557M
| $109K | ﹤0.01% |
6,967
+3,784
| +119% | +$59.4K |
|
2510
Artesian Resources
ARTNA
$345M
| $109K | ﹤0.01% |
2,855
+777
| +37% | +$29.7K |
|
2511
Viking Therapeutics
VKTX
$2.89B
| $109K | ﹤0.01% |
17,330
+6,627
| +62% | +$41.6K |
|
|
ATRS
2512
DELISTED
Antares Pharma, Inc.
ATRS
| $108K | ﹤0.01% |
29,607
+23,136
| +358% | +$84.2K |
|
2513
Regional Management Corp
RM
$418M
| $107K | ﹤0.01% |
1,846
+1,529
| +482% | +$89K |
|
2514
Akero Therapeutics
AKRO
$3.56B
| $107K | ﹤0.01% |
4,798
+3,857
| +410% | +$86.2K |
|
2515
Axogen
AXGN
$765M
| $107K | ﹤0.01% |
6,786
+5,501
| +428% | +$86.9K |
|
|
RDUS
2516
DELISTED
Radius Health, Inc.
RDUS
| $107K | ﹤0.01% |
8,619
+6,849
| +387% | +$85K |
|
2517
i3 Verticals
IIIV
$730M
| $107K | ﹤0.01% |
4,407
+3,592
| +441% | +$87K |
|
2518
Adaptive Biotechnologies
ADPT
$2.01B
| $106K | ﹤0.01% |
3,123
+1,447
| +86% | +$49.2K |
|
2519
Citizens & Northern Corp
CZNC
$314M
| $106K | ﹤0.01% |
4,200
+2,225
| +113% | +$56.2K |
|
2520
Safe Bulkers
SB
$461M
| $106K | ﹤0.01% |
20,440
+8,663
| +74% | +$44.8K |
|
2521
MVB Financial
MVBF
$309M
| $106K | ﹤0.01% |
2,464
+1,310
| +114% | +$56.1K |
|
2522
Altimmune
ALT
$324M
| $106K | ﹤0.01% |
9,330
+5,909
| +173% | +$66.8K |
|
2523
National Research Corp
NRC
$369M
| $105K | ﹤0.01% |
2,495
+2,005
| +409% | +$84.6K |
|
2524
FRP Holdings
FRPH
$481M
| $105K | ﹤0.01% |
3,746
+1,924
| +106% | +$53.8K |
|
2525
Tootsie Roll Industries
TR
$2.89B
| $105K | ﹤0.01% |
3,871
-642
| -14% | -$17.4K |
|